-
7m 42sPart 3 | Session 1 5Y Outcomes From the PARTNER 3 Low-Risk Trial
-
6m 43s
-
8m 46sPart 3 | Session 3 Four-Year Outcomes from the EVOLUT Low Risk Trial
-
11m 22s
-
6m 19sPart 3 | Session 5 WATCH-TAVR: WATCHMAN for Patients with AF Undergoing TAVR
-
7m 14s
-
25m 48sPart 1 | Session 1 View from the Thoraxcenter: TCT 23 Late-breaking Science Preview
-
30m 36sPart 1 | Session 2 View from the Thoraxcenter: TCT 23 Late-breaking Science Wrap Up
-
8m 13sPart 2 | Session 1 5 Trials That Will Change My Practice With Dr Kendra Grubb
-
14m 10sPart 2 | Session 2 5 Trials That Will Change My Practice With Dr Mirvat Alasnag
TCT 23 - We are joined by Dr Bernardo Cortese (Ospedale Fate bene Fratelli, IT) for a concise and insightful summary of the late-breaking trials that are expected to have an impact on structural heart disease care.
Trials covered in detail include:
PARTNER 3
Evolut Low Risk
LIFE-BTK
AGENT-IDE
TRANSFORM I
Recorded remotely from Milano, 2023.
Editor: Jordan Rance
Video Specialist: Dan Brent
Stay up-to-date with our regular review series, View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL). In this #TCT2023 edition they provide a short analysis of the most pertinent data from the late-breaking science presentations.
Short, accessible Expert Interviews were conducted with investigators focusing on study design, key results and applicability of the latest data.
More from this programme
Part 1
View from the Thoraxcenter
Part 2
Highlights
Part 3
Interviews
Faculty Biographies
Bernardo Cortese
Dr Bernardo Cortese is Consultant Interventional Cardiologist for coronary and structural heart disease at the Columbus Clinic in Milano, and the Vercelli Hospital in Italy. He is the CEO of the DCB Academy, and Director of Cardiology at Clinical San Carlo in Milano.
Comments